Xenetic Biosciences Inc (XBIO) has a current Price-to-Book (P/B) ratio of 0.84. Compared to its 3-year average P/B ratio of 0.77, the current P/B ratio is approximately 8.74% higher. Relative to its 5-year average P/B ratio of 0.90, the current P/B ratio is about -6.83% higher. Xenetic Biosciences Inc (XBIO) has a Forward Free Cash Flow (FCF) yield of approximately -55.18%. Compared to its 3-year average FCF yield of -60.36%, the current FCF yield is approximately -8.58% lower. Relative to its 5-year average FCF yield of -52.47%, the current FCF yield is about 5.17% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for XBIO competitors is 0.77, providing a benchmark for relative valuation. Xenetic Biosciences Inc Corp (XBIO.O) exhibits a P/S ratio of 1.67, which is 116.4% above the industry average. Given its robust revenue growth of 67.19%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of XBIO increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of XBIO in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is XBIO currently overvalued or undervalued?

What is Xenetic Biosciences Inc (XBIO) fair value?

XBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Xenetic Biosciences Inc (XBIO) is between 1.74 to 3.12 according to relative valuation method.

How does XBIO's valuation metrics compare to the industry average?

The average P/S ratio for XBIO's competitors is 0.77, providing a benchmark for relative valuation. Xenetic Biosciences Inc Corp (XBIO) exhibits a P/S ratio of 1.67, which is 116.40% above the industry average. Given its robust revenue growth of 67.19%, this premium appears sustainable.

What is the current P/B ratio for Xenetic Biosciences Inc (XBIO) as of Mar 04 2026?

As of Mar 04 2026, Xenetic Biosciences Inc (XBIO) has a P/B ratio of 0.84. This indicates that the market values XBIO at 0.84 times its book value.

What is the current FCF Yield for Xenetic Biosciences Inc (XBIO) as of Mar 04 2026?

As of Mar 04 2026, Xenetic Biosciences Inc (XBIO) has a FCF Yield of -55.18%. This means that for every dollar of Xenetic Biosciences Inc's market capitalization, the company generates -55.18 cents in free cash flow.

What is the current Forward P/E ratio for Xenetic Biosciences Inc (XBIO) as of Mar 04 2026?

As of Mar 04 2026, Xenetic Biosciences Inc (XBIO) has a Forward P/E ratio of -0.72. This means the market is willing to pay $-0.72 for every dollar of Xenetic Biosciences Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Xenetic Biosciences Inc (XBIO) as of Mar 04 2026?

As of Mar 04 2026, Xenetic Biosciences Inc (XBIO) has a Forward P/S ratio of 1.67. This means the market is valuing XBIO at $1.67 for every dollar of expected revenue over the next 12 months.

XBIO Valuation